| Feature Type | Standardized | Nominal ANOVA | ||||
|---|---|---|---|---|---|---|
| mRNA | Doxorubicin | FIMM | pan-cancer | AAC | -0.19 | 0.2 |
| mRNA | foretinib | GDSC1000 | pan-cancer | AAC | -0.039 | 0.2 |
| mRNA | JW-7-24-1 | GDSC1000 | pan-cancer | AAC | 0.035 | 0.2 |
| mRNA | PX-12 | CTRPv2 | pan-cancer | AAC | 0.034 | 0.2 |
| mRNA | BRD-K13185470 | CTRPv2 | pan-cancer | AAC | 0.084 | 0.2 |
| mRNA | decitabine:navitoclax (2:1 mol/mol) | CTRPv2 | pan-cancer | AAC | 0.037 | 0.2 |
| mRNA | SMER-3 | CTRPv2 | pan-cancer | AAC | 0.045 | 0.2 |
| mRNA | tivozanib | GDSC1000 | pan-cancer | AAC | 0.041 | 0.2 |
| mRNA | BMS-708163 | GDSC1000 | pan-cancer | AAC | -0.04 | 0.2 |
| mRNA | temsirolimus | CTRPv2 | pan-cancer | AAC | -0.057 | 0.2 |